神经药理学 SCIE

期刊简介估计审稿时候： 约1.0个月

Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).

《神经药理学》颁发神经迷信范畴的高品质首创研讨和批评文章，特别是包罗神经药理学内容的文章。可是，任何神经迷信范畴的论文城市被斟酌。该期刊凡是不接管临床研讨，但可以或许会斟酌人类临床前神经药理学研讨。该期刊只斟酌那些尝试药物的化学布局和成份在文献中很轻易取得或作者在提交的稿件中表露的投稿。只要在特别环境下，才会斟酌自然产物，并且只要在制备体例经由过程迷信手腕明白界说的环境下才会斟酌。《神经药理学》颁发任何长度的文章（首创研讨和批评）。

《Neuropharmacology》(神经药理学)编辑部通信体例为PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OX5 1GB。若是您须要辅佐投稿或润稿办事，您可以或许征询咱们的客服教员。咱们专一于期刊征询办事十年，熟习颁发政策，可为您供给一对一投稿指点，防止您在投稿时频仍碰鼻，节流您的可贵时候，有用晋升颁发机率，确保SCI检索（检索不了全额退款）。咱们视诺言为生命，多方面确保文章宁静失密，在任何环境下都不会泄漏您的小我信息或稿件内容。